Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMEA NASDAQ:INCR NASDAQ:PYXS NASDAQ:VYNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMEABiomea Fusion$1.83+1.1%$1.92$1.29▼$13.07$68.76M-0.131.23 million shs1.03 million shsINCRInterCure$1.54-0.3%$1.53$1.17▼$2.43$70.18M1.1835,598 shs32,648 shsPYXSPyxis Oncology$1.25-6.7%$1.20$0.83▼$5.39$83.01M1.13737,501 shs592,152 shsVYNEVYNE Therapeutics$1.46+9.0%$1.17$0.85▼$4.30$20.38M1.78874,977 shs404,243 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMEABiomea Fusion+1.10%-1.08%-5.67%-16.44%-66.42%INCRInterCure-0.32%+0.99%+3.72%+3.72%-34.68%PYXSPyxis Oncology-6.72%+10.62%-2.34%+17.92%-66.84%VYNEVYNE Therapeutics+8.96%+25.86%+6.57%+2.10%-27.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBMEABiomea Fusion3.2884 of 5 stars3.64.00.00.02.42.50.6INCRInterCure0.6595 of 5 stars0.03.00.00.03.30.00.6PYXSPyxis Oncology2.4095 of 5 stars3.43.00.00.02.70.80.6VYNEVYNE Therapeutics2.9491 of 5 stars3.53.00.00.03.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMEABiomea Fusion 3.18Buy$20.10998.36% UpsideINCRInterCure 0.00N/AN/AN/APYXSPyxis Oncology 2.80Moderate Buy$9.00620.00% UpsideVYNEVYNE Therapeutics 3.00Buy$6.25328.08% UpsideCurrent Analyst Ratings BreakdownLatest VYNE, PYXS, BMEA, and INCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.007/16/2025BMEABiomea FusionCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $9.006/24/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.006/13/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.006/3/2025BMEABiomea FusionPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$7.006/2/2025BMEABiomea FusionPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/19/2025PYXSPyxis OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/15/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.005/6/2025BMEABiomea FusionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $18.005/6/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 7/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMEABiomea FusionN/AN/AN/AN/A$1.42 per shareN/AINCRInterCure$64.55MN/AN/AN/A$2.36 per shareN/APYXSPyxis Oncology$16.15M4.79N/AN/A$2.03 per share0.62VYNEVYNE Therapeutics$605K36.71N/AN/A$3.53 per share0.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMEABiomea Fusion-$138.43M-$3.55N/AN/AN/AN/A-197.71%-134.84%7/30/2025 (Estimated)INCRInterCure-$18.32MN/A0.00∞N/AN/AN/AN/A8/28/2025 (Estimated)PYXSPyxis Oncology-$77.33M-$1.59N/AN/AN/AN/A-57.49%-45.17%8/13/2025 (Estimated)VYNEVYNE Therapeutics-$39.83M-$0.99N/AN/AN/A-6,974.55%-71.89%-58.94%8/13/2025 (Estimated)Latest VYNE, PYXS, BMEA, and INCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025PYXSPyxis Oncology-$0.36N/AN/AN/AN/AN/A8/13/2025Q2 2025VYNEVYNE Therapeutics-$0.24N/AN/AN/A$0.15 millionN/A7/30/2025Q2 2025BMEABiomea Fusion-$0.64N/AN/AN/AN/AN/A5/15/2025Q1 2025PYXSPyxis Oncology-$0.29-$0.35-$0.06-$0.35N/AN/A5/8/2025Q1 2025VYNEVYNE Therapeutics-$0.29-$0.20+$0.09-$0.20$0.05 million$0.20 million5/5/2025Q1 2025BMEABiomea Fusion-$0.84-$0.80+$0.04-$0.80N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMEABiomea FusionN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/AN/AVYNEVYNE TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMEABiomea FusionN/A2.252.25INCRInterCure0.341.731.18PYXSPyxis OncologyN/A7.757.75VYNEVYNE TherapeuticsN/A4.474.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMEABiomea Fusion96.72%INCRInterCure8.34%PYXSPyxis Oncology39.09%VYNEVYNE Therapeutics83.78%Insider OwnershipCompanyInsider OwnershipBMEABiomea Fusion18.42%INCRInterCure0.24%PYXSPyxis Oncology10.60%VYNEVYNE Therapeutics4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMEABiomea Fusion5037.57 million30.65 millionOptionableINCRInterCure350N/AN/AOptionablePYXSPyxis Oncology6061.95 million55.38 millionOptionableVYNEVYNE Therapeutics3015.21 million14.48 millionNot OptionableVYNE, PYXS, BMEA, and INCR HeadlinesRecent News About These CompaniesVYNE Therapeutics Inc. (VYNE) Gets Buy Reaffirmation on Pipeline ProgressJuly 11, 2025 | insidermonkey.comVyne prunes psoriasis trial under FDA hold, but keeps faith in BET inhibitorJuly 2, 2025 | fiercebiotech.comFVYNE Therapeutics Provides Update on VYN202 Program Following FDA Clinical Hold for Psoriasis TrialJuly 2, 2025 | quiverquant.comQVYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202July 2, 2025 | globenewswire.comVYNE Stock Touches 52-Week Low at $0.96 Amid Market ChallengesMay 31, 2025 | investing.comVYNE Therapeutics First Quarter 2025 Earnings: Beats ExpectationsMay 12, 2025 | finance.yahoo.comVYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comVYNE Therapeutics' Psoriasis Drug Trial Halted By FDA Over Toxicity Concerns; Stock Down.April 27, 2025 | nasdaq.comVYNE Therapeutics Inc. Faces FDA Clinical Hold on VYN202 Phase 1b Trial for Plaque PsoriasisApril 27, 2025 | nasdaq.comAnalysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and VYNE Therapeutics (VYNE)April 26, 2025 | markets.businessinsider.comVYNE Therapeutics Inc.: VYNE Therapeutics Provides Update on VYN202 ProgramApril 25, 2025 | finanznachrichten.deVYNE shares tumble after FDA clinical hold on psoriasis drug studyApril 25, 2025 | za.investing.comVyne Crashes After Safety Signal in Dogs Puts Hold on Clinical Trial of Plaque PsoriasisApril 25, 2025 | biospace.comBFDA puts Vyne in a twist, slapping hold on psoriasis trial over testicular toxicity concernsApril 25, 2025 | fiercebiotech.comFFDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On HoldApril 25, 2025 | benzinga.comVYNE Therapeutics Provides Update on VYN202 ProgramApril 25, 2025 | globenewswire.comArtiva Biotherapeutics, Inc.: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical OfficerApril 9, 2025 | finanznachrichten.deArtiva Biotherapeutics Names New Chief Medical OfficerApril 8, 2025 | marketwatch.comVYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 20, 2025 | markets.businessinsider.comVYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 20, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerBigBear.ai: Why a 90% Rally Could Be Just the StartBy Jeffrey Neal Johnson | July 10, 2025View BigBear.ai: Why a 90% Rally Could Be Just the StartBest Prime Day Ever? Here Are the Prime Winners Riding the WaveBy Thomas Hughes | July 14, 2025View Best Prime Day Ever? Here Are the Prime Winners Riding the WaveVYNE, PYXS, BMEA, and INCR Company DescriptionsBiomea Fusion NASDAQ:BMEA$1.83 +0.02 (+1.10%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.83 +0.00 (+0.22%) As of 07/25/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.InterCure NASDAQ:INCR$1.54 -0.01 (-0.32%) Closing price 07/25/2025 03:57 PM EasternExtended Trading$1.56 +0.03 (+1.63%) As of 07/25/2025 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.Pyxis Oncology NASDAQ:PYXS$1.25 -0.09 (-6.72%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.28 +0.03 (+2.32%) As of 07/25/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.VYNE Therapeutics NASDAQ:VYNE$1.46 +0.12 (+8.96%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.45 -0.01 (-0.96%) As of 07/25/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
